Anemia
From the Journals
Two iron chelators better than one for thalassemia major
In a single-center study, deferasirox plus deferoxamine significantly decreased cardiac iron and serum ferritin, but deferasirox alone did not.
From the Journals
Timing, volume of transfusion may not matter in children with severe anemia
The TRACT trial showed no significant differences in 28-day mortality or other clinical outcomes by transfusion timing or volume.
From the Journals
Hemoglobin levels are associated with long-term dementia risk
Both low and high levels of hemoglobin are linked with an increased risk of dementia, according to a population-based study of adults in the...
Conference Coverage
Sickle cell unit running 24/7 reduces readmissions, emergency visits
FORT LAUDERDALE, FLA. – An analysis of an around-the-clock sickle cell unit showed significant reductions in per-patient health care utilization...
Conference Coverage
Noninvasive prenatal test may detect sickle cell disease
FORT LAUDERDALE, FLA. – Early data for a noninvasive prenatal test shows it could have the potential to accurately detect sickle cell disease.
Conference Coverage
Crizanlizumab shows posttreatment effect in sickle cell
FORT LAUDERDALE, FLA. – High-dose crizanlizumab may have a beneficial effect on vaso-occlusive events in sickle cell disease patients up to a year...
Conference Coverage
Study: Why urban sickle cell patients quit hydroxyurea
Conference Coverage
Femoral head decompression relieves SCD hip pain
FORT LAUDERDALE, FLA. – Femoral head core decompression with bone marrow aspirate concentrate appears to reduce hip joint pain for sickle cell...
Conference Coverage
Orthopedic complications in sickle cell require prompt action
FORT LAUDERDALE, FLA. – Orthopedic crises are common in patients with sickle cell disease, and consultation with an orthopedic surgeon is...
Conference Coverage
Insurance-related barriers impede L-glutamine access
FORT LAUDERDALE, FLA. – Just one in five patients prescribed L-glutamine were still taking the drug after 10 months, according to a new real-world...
Conference Coverage
Oral voxelotor improves hemoglobin in sickle cell disease
AMSTERDAM – The investigational agent may have disease modifying effects, researchers reported.